Secondary mutations in NRAS, observed in 20%–30% of resistant cases, enable melanoma cells to bypass BRAF blockade by reactivating the MAPK/ERK signaling cascade, facilitating continued cell proliferation (Feng et al., 2019; Alqathama, 2020). Here, NRAS is linked to melanoma.